In pursuit of new anti-angiogenic therapies for cancer treatment.

Abstract

Despite advances in surgery, radiation therapy, and chemotherapy, patients with cancer have a poor prognosis. Sustained aberrant tumor angiogenesis and metastasis is a major obstacle for effective cancer treatment. Just a few years ago, few would argue that one of the key success stories of the modern cancer medicine were the anti-angiogenic drugs targeting the vascular endothelial growth factor (VEGF) signaling pathway approved by FDA. This initial success inspired many researchers to search for new anti-angiogenic targets and drugs with the hope that one day, anti-angiogenic therapy might really become the panacea for cancer patients. Unfortunately, the limited clinical benefits achieved with anti-angiogenic drugs conflicts with the widely accepted notion that angiogenesis is a key event in tumor progression. Emerging data indicate that unique characteristics of the tumor vasculature within the tumor microenvironment may hold the key for success of anti-angiogenic therapy. In particular, the molecular and cellular alterations that sustain aberrant tumor angiogenesis in the face of angiogenic inhibitors represents novel targets for rationally designing and improving current anti-angiogenic strategies.

• Authors: Jun Cai, Song Han, Ruan Qing, Daiqing Liao, Brian Law, Michael E Boulton
• Journal: Frontiers in bioscience (Landmark edition) (Front Biosci (Landmark Ed)) Vol. 16 Issue 3 Pg. 803-14 (01 01 2011) ISSN: 2768-6698 [Electronic] Singapore
• PMID: 21196204 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Benzenesulfonates
• Indazoles
• Indoles
• Oligonucleotides
• Phenylurea Compounds
• Pyridines
• Pyrimidines
• Pyrroles
• Quinazolines
• Recombinant Fusion Proteins
• Sulfonamides
• aflibercept
• Niacinamide
• Bevacizumab
• pazopanib
• Sorafenib
• Receptors, Vascular Endothelial Growth Factor
• imetelstat
• cediranib
• Sunitinib

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents (therapeutic use)
• Benzenesulfonates (therapeutic use)
• Bevacizumab
• Drug Resistance, Neoplasm
• Humans
• Indazoles
• Indoles (therapeutic use)
• Neoplasms (blood supply, drug therapy)
• Neovascularization, Pathologic (drug therapy)
• Niacinamide (analogs & derivatives, therapeutic use)
• Oligonucleotides
• Phenylurea Compounds
• Pyridines (therapeutic use)
• Pyrimidines (therapeutic use)
• Pyrroles (therapeutic use)
• Quinazolines (therapeutic use)
• Receptors, Vascular Endothelial Growth Factor
• Recombinant Fusion Proteins (therapeutic use)
• Sorafenib
• Sulfonamides (therapeutic use)
• Sunitinib
• Tumor Microenvironment